AUTHOR=Zhang Yang , Jin Fangfang , Wei Xing , Jin Qiuyu , Xie Jingri , Pan Yujia , Shen Wenjuan 

TITLE=Chinese herbal medicine for the treatment of chronic fatigue syndrome: A systematic review and meta-analysis

JOURNAL=Frontiers in Pharmacology

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.958005

DOI=10.3389/fphar.2022.958005

ISSN=1663-9812

ABSTRACT=<p><bold>Objectives:</bold> This meta-analysis aimed to assess the effectiveness and safety of Chinese herbal medicine (CHM) in treating chronic fatigue syndrome (CFS).</p><p><bold>Methods:</bold> Nine electronic databases were searched from inception to May 2022. Two reviewers screened studies, extracted the data, and assessed the risk of bias independently. The meta-analysis was performed using the Stata 12.0 software.</p><p><bold>Results:</bold> Eighty-four RCTs that explored the efficacy of 69 kinds of Chinese herbal formulas with various dosage forms (decoction, granule, oral liquid, pill, ointment, capsule, and herbal porridge), involving 6,944 participants were identified. This meta-analysis showed that the application of CHM for CFS can decrease Fatigue Scale scores (WMD: –1.77; 95%CI: –1.96 to –1.57; <italic>p</italic> &lt; 0.001), Fatigue Assessment Instrument scores (WMD: –15.75; 95%CI: –26.89 to –4.61; <italic>p &lt;</italic> 0.01), Self-Rating Scale of mental state scores (WMD: –9.72; 95%CI:–12.26 to –7.18; <italic>p &lt;</italic> 0.001), Self-Rating Anxiety Scale scores (WMD: –7.07; 95%CI: –9.96 to –4.19; <italic>p</italic> &lt; 0.001), Self-Rating Depression Scale scores (WMD: –5.45; 95%CI: –6.82 to –4.08; <italic>p</italic> &lt; 0.001), and clinical symptom scores (WMD: –5.37; 95%CI: –6.13 to –4.60; <italic>p</italic> &lt; 0.001) and improve IGA (WMD: 0.30; 95%CI: 0.20–0.41; <italic>p &lt;</italic> 0.001), IGG (WMD: 1.74; 95%CI: 0.87–2.62; <italic>p &lt;</italic> 0.001), IGM (WMD: 0.21; 95%CI: 0.14–0.29; <italic>p &lt;</italic> 0.001), and the effective rate (RR = 1.41; 95%CI: 1.33–1.49; <italic>p &lt;</italic> 0.001). However, natural killer cell levels did not change significantly. The included studies did not report any serious adverse events. In addition, the methodology quality of the included RCTs was generally not high.</p><p><bold>Conclusion:</bold> Our study showed that CHM seems to be effective and safe in the treatment of CFS. However, given the poor quality of reports from these studies, the results should be interpreted cautiously. More international multi-centered, double-blinded, well-designed, randomized controlled trials are needed in future research.</p><p><bold>Systematic Review Registration</bold>: [<ext-link ext-link-type="uri" xlink:href="https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022319680" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022319680</ext-link>], identifier [CRD42022319680].</p>